Nakagami Y, Minowa T, Tozuka K, Hiraoka Y, Chin H
Cancer Chemother Pharmacol. 1983;11 Suppl:S47-50. doi: 10.1007/BF00256718.
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%-80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy, followed by administration of PSK and carboquone (CQ) in small amounts as maintenance therapy continuously for about 3 years, and the course was observed. In both consolidation and maintenance groups various non-specific immunoparameters were superior in groups receiving combined immunotherapeutic agents. Thus, the use of immunotherapeutic agents in combination with chemotherapeutic agents was considered to be effective. The 3-year recurrence rate was only 8% in the multidisciplinary treatment group, while that in the non-multidisciplinary treatment group was 61%. This approach, especially with chemoimmunotherapy (ADM and OK-432) as a consolidation therapeutic mode, is therefore considered to be useful for the prevention of recurrence.
据说膀胱癌（移行细胞癌）即使在肿瘤切除后，复发率仍约为45%-80%。为预防此类复发，设计并研究了多学科治疗方法。该治疗方法设计为三个阶段：诱导、巩固和维持治疗。在手术切除肿瘤后，给予OK-432和阿霉素（ADM）作为巩固治疗，随后持续约3年小剂量给予PSK和卡波醌（CQ）作为维持治疗，并观察整个疗程。在巩固治疗组和维持治疗组中，接受联合免疫治疗药物的组的各种非特异性免疫参数均更优。因此，免疫治疗药物与化疗药物联合使用被认为是有效的。多学科治疗组的3年复发率仅为8%，而非多学科治疗组为61%。因此，这种方法，尤其是以化学免疫疗法（ADM和OK-432）作为巩固治疗模式，被认为对预防复发有用。
